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Berberine and its derivatives display potent analgesic, anti-inflammatory and anticancer
activity. Here we aimed at characterizing the mechanism of action of berberine in the gastro-
intestinal (GI) tract and cortical neurons using animal models and in vitro tests.
Methods
The effect of berberine was characterized in murine models mimicking diarrhea-predomi-
nant irritable bowel syndrome (IBS-D) symptoms. Then the opioidantagonists were used to
identify the receptors involved. Furthermore, the effect of berberineon opioid receptors
expression was established in the mouse intestine and rat fetal cortical neurons.
Results
In mouse models, berberine prolonged GI transit and time to diarrhea in a dose-dependent
manner, and significantly reduced visceral pain. In physiological conditions the effects of
berberine were mediated by mu- (MOR) and delta- (DOR) opioidreceptors; hypermotility,
excessive secretion and nociception were reversed by berberine through MOR and DOR-
dependent action. We also found that berberine increased the expression of MOR and
DOR in the mouse bowel and rat fetal cortical neurons.
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Conclusion
Berberine significantly improved IBS-D symptoms in animal models, possibly through mu-
and delta- opioid receptors. Berberine may become a new drug candidate for the successful
treatment of IBS-D in clinical conditions.
Introduction
Berberine is present in several plant species, which are common in the Eastern hemisphere. It
has a long history in traditional Chinese medicine, where it has been used to treat diarrhea and
gastroenteritis due to its anti-microbial, anti-motility and anti-secretory properties. Berberine
and its derivatives also display a potent analgesic[1], anti-inflammatory[2] and anticancer
activity [3];they also have a potential therapeutic effect on diabetes [4], hyperlipidemia[5], car-
diovascular diseases [6], and central nervous system (CNS) disorders[7]. Of note, the antide-
pressant-like activity of berberine involves inhibition of monoamine oxidase [8].However,
sigma-1 receptor and nitric oxide signaling may also be targeted by berberine[9]. Recently, pro-
gression of visceral hypersensitivity to colorectal distension controlled by berberine has been
reported[1]. The antinociceptive and antidepressant-like activity of berberine underlines its
therapeutic potential for the treatment of patients with irritable bowel syndrome (IBS)[10,11].
Although we found that [12] berberine plays an inhibiting role on gastrointestinal motility in
rodents, which is closely related to that of the endogenous opioid system, the mechanism has
not been fully clarified by now.
Mu opioid receptors (MORs), which belong to the opioid receptor family, are involved in
diverse physiological and pathological states, and MOR agonists were found to produce analge-
sia, alleviate depression symptoms, and relieve stress and anxiety [13].Furthermore, genetic
deletion of MOR and delta opioid receptor (DOR), but not kappa opioid receptor (KOR)as
shown to increase anxiety symptoms and depressive-like behavior [14]. On the other hand,
opioid receptor agonists were found to attenuate visceral hyperalgesia and inhibit an enhanced
excitability of colonic sensory neurons [15]. MOR activation reduces persistent pain and
improves negative emotional states. Moreover, clinical trials have been initiated to assess the
effectiveness of MOR agonists in chronic pain and depression[16].
DOR has high sequence similarity to MOR, yet different physiological and pharmacological
property. As reviewed by Pradhan et al.[17], preclinical data confirmed that DOR activation
reduces persistent pain and improves negative emotional states.
The aim of this study was to assess the efficacy of berberine in relieving IBS-D symptoms in
mice through employing currently available animal models of hypermotility, excessive secre-
tion and abdominal pain. We also explored the mechanism of action of berberine in the mouse
GI tract and characterized opioid receptor expression after berberine treatment in mouse
bowel and rat fetal cortical neurons. We conclude by suggesting that berberine produces potent
antinociception and reverses GI hypermotility in an opioid-receptor dependent manner.
Methods
Animals
Male BALB/c mice, weighing 25-30g and female Sprague-Dawley (SD) rats pregnant for 18
days were purchased from the Experimental Animal Center of Tongji University, Shanghai,
China. Animals were housed at a constant temperature of 22°C and kept at a constant photope-
riod (12:12-h light-dark cycle) in sawdust-lined plastic cages with free access to standard labo-
ratory irradiated chow (purchased from XieTong company, China)and tap water. All
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operations were performed under aseptic conditions. Experimental procedures complied with
international guidelines for care and use of laboratory animals and were approved by the Ani-
mal Ethics Committee of Tongji University, Shanghai, China.
Whole gut transit time
In the morning (7 a.m.) of each experimental round, mice were transferred to individual empty
plastic cages (devoid of bedding) and were left to acclimatize to the cage for 1 h. Mice were
then injected i.p. with vehicle (saline) or berberine (0.5, 1, 2 or 5mg/kg) and 15 min later
gavaged with 150 ml of prewarmed (37°C) Evans blue marker (5% Evans blue, 5% gum Arabic
in drinking water). Mice were returned to their individual cages. The time from the end of
gavaging to the first blue faecal pellet was measured in minutes and constituted the whole gut
transit time. In further experiments the non-selective opioid receptor antagonist naloxone
(NAL, 1mg/kg), and selective MOR(β-funaltrexamine, β-FNA,1mg/kg),DOR (naltrindole,
NTI, 1 mg/kg) or KOR (nor-binaltorphimine, nor-BNI,10mg/kg) antagonists were adminis-
tered i.p. 15 min prior to vehicle or berberine (BER, 2mg/kg).
Castor oil-induced diarrhea
Berberine (0.5 or 1 mg/kg) or vehicle (saline) were injected i.p. 15 min before p.o. administra-
tion of castor oil (0.2 ml/mouse) and the time elapsed until unformed watery stools appeared
was recorded.
The non-selective opioid receptor antagonist naloxone (1 mg/kg)and the selective opioid
receptor antagonists were administered i.p. 15 min prior to berberine (0.5 mg/kg, i.p.)
treatment.
Stress-induced hypermotility
One day before the experiment, mice were divided into two groups: control and stressed by the
novel environment (NE-stressed). Animals from the control group were separated from each
other and placed into individual cages with free access to chow and water to accommodate
overnight. On the day of the experiment, mice received berberine (0.5 and 1.0 mg/kg, i.p.) or
vehicle. Fifteen minutes later all animals were placed in individual cages without access to food
and water. One hour later, the number of faecal pellets in each cage was counted.
Mustard oil and capsaicin-induced visceral pain
Behavioral pain-related responses to intracolonic (i.c.) administration of mustard oil (MO) and
capsaicin solution were determined as described previously[18]. Fifteen minutes after i.p. injec-
tion of berberine (0.5 and 1 mg/kg in MO test and 0.5, 1, and 5mg/kg in capsaicin test), 50 μL
of MO (1% vol/vol dissolved in 70% ethanol) or capsaicin (0.3% w/v in 10% ethanol-10%
Tween 80–80% saline) were administered into the colon of anesthetized mice using a fine cath-
eter (external diameter 0.61 mm, 4 cm long, Minipack, Portex, Hythe, UK). Vaseline was
applied to the perianal area to avoid the stimulation of somatic areas by contact with MO or
capsaicin. After the administration of MO or capsaicin, the animals were placed in individual
plastic cages in a quiet environment. Five minutes later, spontaneous pain-related responses:
licking of the abdomen, stretching the abdomen, squashing the lower abdomen against the
floor, and abdominal retractions were counted for 20 min.
The non-selective opioid receptor antagonist naloxone (1 mg/kg) and the selective opioid
receptor antagonists were administered i.p. 15 min prior to berberine in the MO induced pain
test.
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Behavioral responses to acetic acid induced pain test
The acetic acid test was performed in the morning as described recently[18]. Fifteen minutes
after i.p. injection of berberine (0.5, 1 and 5 mg/kg), mice received an i.p. injection of an acetic
acid solution (0.5%, vol/vol in 0.9% NaCl). Animals were then placed individually in empty
cages and after 5 min abdominal stretchings were counted for 15 min in 5 min intervals. A typ-
ical stretch was characterized by an elongation of the body and the development of tension in
the abdominal muscles and hind paws. Vehicle (saline) was used in control experiments.
Expression of opioid receptors
Study material. To investigate the effect of berberine on opioid receptor expression in the
ileum and the colon, mice were injected with berberine (0.5, 1, 2 and 5mg/kg,i.p.) and 45 min
later sacrificed by cervical dislocation. Full-thickness segments of ileum and colon were
removed and divided into two groups; one was kept in -80°C for genetic analysis and the other
saved in 4% PFA for histological evaluation.
The expression of opioid receptors at mRNA level was also evaluated in fetal cortical neu-
rons. Briefly, whole Sprague Dawley rat fetus brains were removed and cortices dissected in
HBSS and trypsinized (0.25% trypsin in PBS at 37°C for 12 min)[19].Trypsin was then neutral-
ized by DMEM/F12 with 10% FBS. Dissociated cells were filtered through 40 μmmeshes (BD
Biosciences, Bedford, MA) and plated in 35or 60mm dishes pre-treated for at least 2 h with poly-
D-Lysine (Sigma, St. Louis, MO). After incubation for 18-24h, the non-adherent cell suspension
was discarded and neurobasal media supplemented with 2% B27 (Invitrogen, Carlsbad, CA,
USA) was added. Neurons were cultured for 7 days to collection. Berberine(10-8mol/L) was
added and cells maintained in culture for the 0.5, 1, and 2 days prior to material collection.
RNA extraction and real-time RT-PCR. Total RNA was isolated from fetal rat primary
neurons using TRIzol solution (Invitrogen, Carlsbad, CA, USA) in accordance with the manu-
facturer's instructions. Reverse transcription was performed in a 10 μl reaction system with
1 μg total RNA treated with RT-PCR kit to synthesize first-strand cDNA (TAKARA, Japan).
The resulting cDNA was amplified using KAPA qPCR Master Mix (KAPA, Boston, USA) and
the following primers(Invitrogen, USA):
OPRM (for mouse or rat MOR): 5'- CAACTTGTCCCACGTTGATG -3' (F)
and 5'- TCCAAAGAGGCCCACTACAC -3' (R);
OPRD (for mouse or rat DOR): 5'- TTGGCTTCAGGTGTTGGGGT -3' (F)
and 5'- GCGAAGAGGAACACGCAGAT -3' (R);
OPRK (for mouse or rat KOR): 5'- GCAGCCTGAATCCTGTTCTC -3' (F)
and 5'- TCATCCCTCCCACATCTCTC -3' (R);
GAPDH (housekeeping gene): 5'-GGTGAAGGTCGGTGTGAACG-3' (F)
and 5'- GTGAAGACACCAGTAGACTC -3' (R).
Drugs
Naloxone, naltrindole, β-funaltrexamine, nor-binaltorphimine and capsaicin were obtained
from Tocris Bioscience (Tocris, Ellisville, Missouri, USA). Allyl isothiocyanate (mustard oil,
MO) was purchased fromMerck (Darmstadt, Germany). Berberine was purchased from
Shanghai Shifeng Biotechnology Ltd., China. All drugs were dissolved in dimethyl sulfoxide
(DMSO) and diluted in 0.9% saline to final concentrations.
Statistics
PRISM 5.0 (GraphPad Software Inc., La Jolla, CA, USA) was used for statistical analyses. One-
way analysis of variance (ANOVA) followed by Student-Newman-Keuls post hoc test was used
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for analysis of multiple treatment means. P values< 0.05 were considered significant. The data
are expressed as means ± SE.
Results
Berberine inhibits gastrointestinal transit in mice in an opioid receptor-
dependent manner
As shown in Fig 1A, berberine(0.5, 1, 2 and 5 mg/kg, i.p.) prolonged the whole gut transit time
in mice in a dose-dependent manner. The effect of berberine(2 mg/kg, i.p.) was blocked by the
i.p. administration of the non-selective opioid receptor antagonist naloxone, the selective MOR
antagonist β-funaltrexamine and DOR antagonist naltrindole, but not KOR antagonist nor-
binaltorphimine (Fig 1B).
Berberine reduces diarrhea and gastrointestinal hypermotility in mice
Berberine(0.5 and 1 mg/kg,i.p.) significantly prolonged time to diarrhea in a mouse model
induced by oral administration of castor oil (Fig 2A). The effect of berberine(0.5 mg/kg, i.p.)
was blocked by the i.p. administration of naloxone and the selective MOR antagonist β-funal-
trexamine, but not DOR or KOR antagonists (Fig 2B).
At last as shown in Fig 2C, berberine(0.5 and 1 mg/kg, i.p.) significantly reduced the number
of fecal pellets in the mouse model of GI hypermotility induced by novel environment (NE)-
related stress.
Antinociceptive effect of berberine in mouse models of pain
Berberine(0.5 and 1 mg/kg, i.p.) significantly reduced the number of pain-related behaviors in
the mouse model of MO-induced visceral pain (Fig 3A).Interestingly, the effect of berberine
(0.5 mg/kg, i.p.) was blocked by the i.p. administration of the non-selective opioid receptor
antagonist naloxone and the selective MOR and DOR antagonists (β-funaltrexamine and nal-
trindole, respectively) (Fig 3B).
Moreover, the i.p. administration of berberine(0.5, 1 and 5 mg/kg)produced a potent, dose-
dependent antinociceptive effect in the capsaicin (i.c.) and acetic acid (i.p.) (Fig 3C and 3D,
respectively) mouse model of visceral pain.
Berberine changes opioid receptor expression in mouse intestine
Berberine at the dose of 1, 2 and 5mg/kg increased MOR mRNA expression in the mouse
ileum and at the dose of 2 and 5 mg/kg in the colon (Fig 4A). DOR expression was also
increased in the mouse GI tissues; however, in the colon only the highest dose of berberine
(5 mg/kg) produced statistically significant results (Fig 4B). No effect of berberine on KOR
mRNA expression was found in the mouse GI tract (Fig 4C).
Berberine changes opioid receptor expression in rat brain cortex
Previous studies have demonstrated that opioid receptor agonists affect neuronal activity in the
CNS [20]; furthermore, primary culture of cortical neurons is widely used in the research on
neurological disorders[21].However, owing to difficulties in dissection and culture of mouse
fetal cortical neurons, a universally accepted protocol for their derivation has not yet been
determined. As a result, the effect of berberine was examined on cultured rat fetal cortical
neurons.
As shown in Fig 5A, nearly all rat fetal cortical neurons were β-tubulin, MOR and DAPI-
positive after7 days of culture. Determination of neuronal purity using dark field imaging
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showed that the percentage of β-tubulin-immunostained neurons was over 95%. Incubation of
cortical neurons with berberine (10−8 mol/L, added to a 7-day culture 1 and 2 days before col-
lection) significantly increased the mRNA expression of MOR compared with the control
group (Fig 5B).
Fig 1. Effect of berberine (BER) alone or in presence of opioid antagonists on whole gut transit time in
mice.Data are mean ± SE (n = 6–10). A: I.p. berberine (0.5, 1, 2 and 5 mg/kg) prolonged the whole gut transit
time in a dose-dependent manner. **P < 0.01, ***P < 0.001 vs. control. B: I.p. naloxone (NAL, 1 mg/kg),
β-funaltrexamine (β-FNA,1 mg/kg) and naltrindole (NTI, 1 mg/kg), but not nor-binaltorphimine (nor-
BNI,10 mg/kg) blocked the effects of berberine(BER, 2 mg/kg, i.p.) on the whole gut transit time. *P < 0.05,
**P < 0.01 and ***P < 0.001, vs. control; #P < 0.05 and ##P < 0.01, berberine vs. berberine + antagonists.
doi:10.1371/journal.pone.0145556.g001
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Fig 2. Effect of berberine (BER) on diarrhea and gastrointestinal hypermotility in mice.Data are
mean ± SE (n = 6–10). A: I.p. berberine (0.5 and 1 mg/kg) prolonged time to diarrhea in the mouse model
induced by oral administration of castor oil. ***P < 0.001, vs. control. B: I.p. opioid antagonists: naloxone
(NAL, 1 mg/kg) and β-funaltrexamine (β-FNA,1 mg/kg), but not naltrindole (NTI, 1 mg/kg) or nor-
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Of note, the increase of DOR mRNA expression after berberine(10-8mol/L) (only 1 day
before collection) treatment was observed in the cortical neurons cultured for 7-day, as com-
pared with control (Fig 5C). No effect of berberine on the mRNA expression of KOR was
found in the cortical neuron culture (Fig 5D).
binaltorphimine (nor-BNI,10 mg/kg) blocked the effects of berberine(BER, 0.5 mg/kg, i.p.) in the mouse model
of castor oil-induced diarrhea. *P < 0.05, **P < 0.01, ***P < 0.001, vs. control; #P < 0.05, berberine
+ antagonists vs. berberine alone. C: I.p.berberine (0.5 and 1 mg/kg)reduced the number of fecal pellets in
the mouse model of hypermotility induced by NE (novel environment)-related stress. ###P < 0.001, non-
treated NE-stressed vs. non-treated control; **P < 0.01, *** P < 0.001, vs. non-treated NE-stressed.
doi:10.1371/journal.pone.0145556.g002
Fig 3. Antinociceptive effect of berberine (BER) in mousemodels of pain.Data are mean ± SE
(n = 6–10).A: I.p. berberine (0.5 and 1 mg/kg)reduced the number of pain-related behaviors in the mustard oil
(i.c.)-induced model of visceral pain. ***P < 0.001, vs. control. B: I.p. opioid antagonists naloxone (NAL,
1 mg/kg), β-funaltrexamine (β-FNA,1 mg/kg) and naltrindole (NTI, 1 mg/kg), but not nor-binaltorphimine (nor-
BNI,10 mg/kg)blocked the effects of berberine(BER, 0.5 mg/kg, i.p.)on the number of pain-related behaviors
in the mustard oil model.*P < 0.05; ***P < 0.001, vs. control; #P < 0.05; ##P < 0.01, berberine + antagonists
vs. berberine alone. C: I.p. berberine (0.5, 1 and 5 mg/kg)reduced the number of pain-related behaviors in the
capsaicin-induced model of visceral pain. **P < 0.01; ***P < 0.001, vs. control. D: I.p. berberine (0.5, 1 and
5 mg/kg)reduced the number of pain-related writhing induced by i.p. administration of acetic acid.**P < 0.01;
***P < 0.001, vs. control.
doi:10.1371/journal.pone.0145556.g003
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Fig 4. Effects of berberine (BER) on opioid receptor expression in the mouse ileum and colon. A:
Berberine i.p. (1, 2 and 5 mg/kg) increased MORmRNA expression in the mouse ileum in a dose-dependent
manner, and berberine i.p. (2 and 5 mg/kg) increased MOR expression in the mouse colon. *P<0.05,
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Discussion
Patients with IBS-D suffer markedly from loose and frequent stools, and from the associated
urgency and fear of incontinence, which generate panic and anxiety. Furthermore, mental dis-
orders constitute an important factor in intestinal dysfunction, and the disease itself is often
closely related to mental ailments, such as anxiety, anger, depression, and fear [22]. Another
main symptom of IBS is abdominal pain, presented in most patients [23].
**P<0.01 and ***P<0.001, vs. ileum control; # P<0.05, ### P<0.001, vs. colon control. B: Berberine i.p. (1, 2
and 5 mg/kg) increased DORmRNA expression in the mouse ileum in a dose-dependent manner, and
berberine i.p. (5 mg/kg) increased MOR expression in the mouse colon. *P<0.05, **P<0.01 and
***P<0.001, vs. ileum control; # P<0.05 vs. colon control. C: Berberine i.p. (0.5, 1, 2 and 5 mg/kg) had no
effect on KORmRNA expression in the mouse ileum and colon.
doi:10.1371/journal.pone.0145556.g004
Fig 5. Effects of berberine (BER) on opioid receptors expression of mRNA level in rat fetal cortical
neurons. A: Fetal cortical cells cultured for 7 days expressed MOR (β-tubulin+ in red, MOR+ in green, DAPI+
in blue and merged). B: Berberine (BER, 10-8mol/L) significantly increased MORmRNA expression when
added 1.0 and 2.0 day before cell collection in 7-day culture (***P<0.001 compared with control). C:
Berberine (BER 10-8mol/L) increased DORmRNA expression when added1.0day before cell collection in
7-day culture. *P<0.05 compared with control. D: Berberine had no effect on KOR expression in 7 day
cortical neuron cultures.
doi:10.1371/journal.pone.0145556.g005
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In this study, we explored the therapeutic potential of berberine in treating IBS-D using
mouse models mimicking physiological conditions and disease symptoms. We found that ber-
berine prolonged the whole gut transit time; of note, a classic non-selective opioid antagonist
naloxone, as well as selective MOR (β-funaltrexamine) and DOR (naltrindole) blocked the
anti-motility effect, suggesting that both receptor types may be involved in regulation of whole
gut motility by berberine. This is in line with earlier reports showing that berberine inhibits
myoelectrical activity and GI transit through the endogenous opioid system[12].In the recent
years, MOR-DOR interactions were studied in detail and it was found that MOR and DOR
may form heteromers, if co-expressed[24]. The co-expression of MOR and DOR and func-
tional interaction has been widely reported. For example, MOR was shown to co-internalize
with DOR and target lysosomal degradation after treatment with a DOR agonist[25]. More-
over, DOR can alter the functions and the trafficking of MOR[26]. In the present study we
showed that the activation of MOR by berberine may simultaneously affect DOR function in
physiological conditions. However, berberine prolonged the time to diarrhea in the mouse
model induced by orally administered castor oil exclusively in a β-funaltrexamine-dependent
manner. These results suggest that MOR is principally responsible for berberine action in
pathophysiological conditions.
Earlier reports demonstrate that the activation of MOR and DOR controls pain signaling
[27,28]. For example, it was found that peripheral MOR and DOR play a major role in the
tonic inhibition of mechanical allodynia[29,30]and MOR and DOR agonists alleviate mechani-
cal pain and relieve heat and mechanical hyperalgesia[31,32]; opioid receptor agonists of differ-
ent background and chemical structure also produce antinociception in inflammatory or
chemically‐induced pain (for example [18,33,34]).In line, our results showed that berberine
significantly relieved visceral pain induced by mustard oil, capsaicin and acetic acid which
blocked by MOR and DOR antagonists in mustard oil test, confirming crucial role of periph-
eral MOR and DOR in berberine-mediated action.
By now there have been no studies investigating in detail the interaction of berberine in the
endogenous opioid system. Here we showed that the administration of berberine in mice sig-
nificantly enhanced MOR and DOR mRNA expression in ileum and colon.
Since berberine was shown to easily cross the blood brain barrier after systemic administra-
tion[1]and may thus affect CNS, we also investigated the effect of berberine on opioid receptor
expression in fetal cortical neurons. Interestingly, MOR expression was significantly enhanced
after berberine treatment in 7 days cortical neurons, while DOR was up-regulated also in 7 day
neurons.
Earlier reports show that the activation of MOR and DOR reduces depression, possibly as a
result of stress or anxiety relief [35,36]. Several studies revealed that already a single treatment
with MOR and DOR agonists produce antidepressant-like effects in the forced swimming test,
which is one of the most popular animal models for screening antidepressants [37,38]. Further-
more, acute administration of the selective MOR agonists, such as methadone, fentanyl, mor-
phine, hydrocodone, buprenorphine, and nalbuphine in an intracranial self-stimulation (ICSS)
blocked both stimulation of stretching and depression produced by lactic acid[39].Recently a
novel DOR agonist, KNT-127 demonstrated antidepressant-like and antinociceptive effects in
mice without producing convulsions[40]. The fact that berberine simultaneously acts through
MOR and DOR, but also enhances their expression in the CNS may have vital implications in
the treatment of anxiety symptoms and depressive-like behavior, which are typical for IBS
patients. This action must not be overlooked in further, clinical trials of berberine.
Finally, patients with diarrhea-predominant irritable bowel syndrome (IBS-D) suffer
markedly from loose and frequent stools, with the associated urgency and a fear of inconti-
nence. Another main symptom of IBS is abdominal pain, presented in most patients.
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Furthermore, this disease itself is often closely related to mental ailments. According to our
berberine mechanism research here, it encourages to use in the anti-IBS treatment. However,
further clinical studies are needed to investigate this mechanism and effects in detail.
Conclusion
Berberine alleviates disease symptoms in mouse models mimicking the symptoms of IBS-D.
Further experiments in animal models and in vitro cell cultures suggested that the effect of ber-
berine on bowel motility and visceral pain may be mediated in MOR and DOR-dependent
manner. Our data validate further use of berberine as an attractive drug in the treatment of
IBS-D, targeting GI symptoms and CNS-related consequences of the disease; we also recom-
mend further clinical studies of this compound.
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